Literature DB >> 15055492

Is the absence of the ossific nucleus prognostic for avascular necrosis after closed reduction of developmental dysplasia of the hip?

Brian T Carney1, David Clark, Christin L Minter.   

Abstract

The presence of the ossific nucleus before reduction of developmental dysplasia of the hip may reduce the rate of avascular necrosis. Forty-eight hips in 45 children who underwent successful closed reduction had at least a 2-year follow-up. Medical records were reviewed for sex, side, Pavlik harness, traction, age at reduction, adductor tenotomy, cast duration, length of follow-up, and subsequent surgery. Prereduction radiographs were reviewed for presence or absence of the ossific nucleus. Avascular necrosis was noted as present if there was evidence of Bucholz and Ogden type II, III, or IV on the postreduction radiographs. Avascular necrosis was noted postreduction in 17 hips. Adductor tenotomy may reduce the rate of avascular necrosis following closed reduction. Delaying closed reduction until the presence of the ossific nucleus can be detected radiographically may reduce the rate of avascular necrosis. The presence of avascular necrosis increases the need for subsequent surgery.

Entities:  

Mesh:

Year:  2004        PMID: 15055492

Source DB:  PubMed          Journal:  J Surg Orthop Adv        ISSN: 1548-825X


  14 in total

1.  Acetabuloplasties at Open Reduction Prevent Acetabular Dysplasia in Intentionally Delayed Developmental Dysplasia of the Hip: A Case-control Study.

Authors:  M Belen Carsi; Nicholas M P Clarke
Journal:  Clin Orthop Relat Res       Date:  2016-05       Impact factor: 4.176

Review 2.  Is Age or Surgical Approach Associated With Osteonecrosis in Patients With Developmental Dysplasia of the Hip? A Meta-analysis.

Authors:  Eduardo N Novais; Mary K Hill; Patrick M Carry; Patricia C Heyn
Journal:  Clin Orthop Relat Res       Date:  2016-05       Impact factor: 4.176

3.  Does open reduction of the developmental dislocated hip increase the risk of osteonecrosis?

Authors:  Renata Pospischill; Julia Weninger; Rudolf Ganger; Johannes Altenhuber; Franz Grill
Journal:  Clin Orthop Relat Res       Date:  2011-06-04       Impact factor: 4.176

4.  The presence of an ossific nucleus does not protect against osteonecrosis after treatment of developmental dysplasia of the hip.

Authors:  Andreas Roposch; Odeh Odeh; Andrea S Doria; John H Wedge
Journal:  Clin Orthop Relat Res       Date:  2011-02-11       Impact factor: 4.176

5.  Does Perfusion MRI After Closed Reduction of Developmental Dysplasia of the Hip Reduce the Incidence of Avascular Necrosis?

Authors:  Alex L Gornitzky; Andrew G Georgiadis; Mark A Seeley; B David Horn; Wudbhav N Sankar
Journal:  Clin Orthop Relat Res       Date:  2016-05       Impact factor: 4.176

6.  Correlation between avascular necrosis and the presence of the ossific nucleus when treating developmental dysplasia of the hip.

Authors:  Sabit Sllamniku; Cen Bytyqi; Ardiana Murtezani; Emir Q Haxhija
Journal:  J Child Orthop       Date:  2013-10-22       Impact factor: 1.548

7.  Developmental dysplasia of the hip.

Authors:  Shahryar Noordin; Masood Umer; Kamran Hafeez; Haq Nawaz
Journal:  Orthop Rev (Pavia)       Date:  2010-09-23

8.  Risk factors for avascular necrosis after closed reduction for developmental dysplasia of the hip.

Authors:  Mathew D Schur; Christopher Lee; Alexandre Arkader; Anthony Catalano; Paul D Choi
Journal:  J Child Orthop       Date:  2016-05-13       Impact factor: 1.548

9.  Avascular necrosis following closed reduction for treatment of developmental dysplasia of the hip: a systematic review.

Authors:  Catharine S Bradley; Daniel C Perry; John H Wedge; M L Murnaghan; Simon P Kelley
Journal:  J Child Orthop       Date:  2016-11-03       Impact factor: 1.548

Review 10.  Association between the ossific nucleus and osteonecrosis in treating developmental dysplasia of the Hip: updated meta-analysis.

Authors:  Rafal Niziol; Michael Elvey; Evangelia Protopapa; Andreas Roposch
Journal:  BMC Musculoskelet Disord       Date:  2017-04-20       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.